Business Context and Reporting Period
This Form 8-K, dated August 12, 2024, reports the completion of a business combination between TenX Keane Acquisition (formerly a Cayman Islands exempted company) and Citius Pharmaceuticals, Inc. (SpinCo). Effective August 5, 2024, TenX domesticated as a Delaware corporation and renamed itself Citius Oncology, Inc. The transaction closed on August 12, 2024. Following the closing, the Company ceased to be a shell company and its common stock began trading on the Nasdaq Capital Market under the symbol CTOR on August 13, 2024. The Company changed its fiscal year-end from December 31 to September 30.
Key Financial Metrics and Capital Structure
The filing details the capital structure immediately following the closing but does not provide historical revenue, profit, or cash flow statements for the combined entity within this specific document (referencing the Final Prospectus for such data).
- Shares Outstanding: 71,304,049 shares of Company Common Stock issued and outstanding immediately after closing.
- Redemptions: Holders of 4,297,828 TenX Ordinary Shares exercised redemption rights, receiving approximately $11.47 per share, totaling $49,296,087.16 from the trust account.
- Trust Account Balance: Approximately $163,498.89 remained in the trust account prior to closing and was used to pay transaction expenses.
- Debt and Promissory Notes:
- Citius Pharma Note: The Company issued an unsecured promissory note to Citius Pharma for $3,800,111 (part of a $10 million capital contribution). This note bears no interest and is repayable upon a financing of at least $10 million.
- Sponsor Notes: The Company issued 119,500 shares to the Sponsor to settle promissory notes totaling $1,195,000 ($660,000 and $535,000). Additionally, a new promissory note for $1,288,532 in transaction expenses was issued to the Sponsor and automatically converted into 128,854 shares on August 13, 2024.
- Ownership Structure: Citius Pharmaceuticals, Inc. owns approximately 92.6% of outstanding shares. Former TenX public shareholders own approximately 1.3%, and the Sponsor (10XYZ Holdings LP) and related parties own approximately 3.1%.
Material Changes Versus Prior Period
The filing represents a fundamental transformation of the registrant:
- Corporate Status: The entity transitioned from a special purpose acquisition company (SPAC) shell to an operating biopharmaceutical company focused on the commercialization of LYMPHIR (denileukin diftitox).
- Control: Citius Pharma now controls approximately 92.6% of the voting power, making Citius Oncology a "controlled company" under Nasdaq rules.
- Accounting Firm: Marcum LLP was dismissed as the independent registered public accounting firm effective August 13, 2024, and replaced by Wolf & Company, P.C.
- Management: The entire board and executive team of TenX resigned. Leonard Mazur was appointed CEO and Chairman, Jaime Bartushak as CFO, Myron Holubiak as Secretary/Treasurer, and Myron Czuczman as Chief Medical Officer.
- Securities: TenX Ordinary Shares, Units, and Rights ceased trading. All SpinCo options were converted to Company options.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Strategy: The Company intends to focus on the development and commercialization of LYMPHIR and future product candidates. It does not intend to pay cash dividends in the foreseeable future.
Risks and Contingencies:
- Capital Needs: The Company explicitly states a need for substantial additional funds.
- Commercialization: Success depends on the ability to commercialize LYMPHIR and obtain regulatory approvals.
- Supply Chain: Risks include the ability to procure cGMP commercial-scale supply and dependence on third-party suppliers.
- Controlled Company Status: As a controlled company, the Company may elect not to comply with certain Nasdaq corporate governance standards (e.g., majority independent board), though it does not currently intend to rely on these exemptions.
- Waivers: Certain closing conditions were waived, including the immediate transfer of the LYMPHIR trademark and FDA notification regarding BLA/IND ownership, which will now occur within 60 days of closing.
Important Facts for Investor Verification
- Trading Symbol: Verify trading activity under the new symbol CTOR on the Nasdaq Capital Market.
- Liquidity Position: Confirm the Company's cash position post-closing, noting the $3.8 million promissory note to Citius Pharma is contingent on future financing.
- Ownership Concentration: Acknowledge that Citius Pharma holds ~92.6% of shares, significantly limiting the voting power of public shareholders.
- Financial Statements: Review the "Unaudited Pro Forma Condensed Combined Financial Information" in the Final Prospectus (File No. 333-275506) for historical financial data, as this 8-K does not contain detailed income statements or balance sheets.
- Regulatory Status: Monitor the transfer of the LYMPHIR trademark and FDA notifications, which were waived for immediate completion and are due within 60 days of August 12, 2024.